Yoshinori Oikawa

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.